Novartis

Pharmaceuticals
NVS
$ 76 (1.5)%
Share price
$ 166 bn
Market Cap
$ 177 bn
Enterprise Value

Carbon footprint

3.6 Ton
GHG emissions per $ 1 mln investment
0.09x the weighted average for S&P 500
FY2021
How is this calculated?
-9.8%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-25%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

Novartis aims to achieve carbon neutrality for Scope 1 + 2 by 2025


This target has not been verified as science based according to SBTi
Novartis's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

-5%
Proj. YOY change in GHG emissions (all Scopes)
Weaker than the -7.1% weighted average for S&P 500
FY2021
How is this calculated?

Novartis aims to achieve net zero for all Scopes by 2040


This target has not been verified as science based according to SBTi
Novartis's actual and proj. GHG emissions (all Scopes) (Kt of CO2e)

GHG emissions and Carbon intensity

Novartis's GHG emissions (market-based) (Kt of CO2e)
Novartis's Carbon intensity (Tons per 1 USDm)

Novartis's carbon footprint

Novartis reported gross GHG emissions (Scope 1 + 2 before carbon offsets) for the twelve months ending 31 December 2021 at 647 Kt (-70 /-9.8% y-o-y). Also positively, carbon intensity was down at 12 t (-2.2 /-15.3% y-o-y).

Novartis's Scope 3 emissions surged to 6,984 Kt (+933/+15% y-o-y). The performance has been erratic recently.

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2025, which translates into the estimated reduction of -162 Kt per annum over the period of FY2022 - FY2025. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Also, the company commits to achieving net zero for all Scopes by 2040, which translates into the estimated reduction of -385 Kt per annum over the period of FY2021 - FY2040. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Novartis aims to achive carbon neutrality across its entire value chain (all Scopes) in 2030. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Novartis also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Swiss multinational pharmaceutical company Novartis commits to reduce absolute scope 1, 2 and 3 GHG emissions 35% by 2030 from a 2016 base-year.

Company environmental metrics

Show more...